Several attorneys in the products liability arena say there are significantly fewer testosterone therapy drug cases being filed nationwide than initially expected.
While maintaining that the cases still have multidistrict litigation and mass tort potential, lawyers attribute the relatively small number of cases to the difficulties in litigating “low T” drug claims, especially in linking heart attacks and strokes—the alleged injuries—to the drugs and not other health factors present in men over 50, the primary users of the drugs.
